JP5937573B2 - 満腹を誘導する方法および組成物 - Google Patents
満腹を誘導する方法および組成物 Download PDFInfo
- Publication number
- JP5937573B2 JP5937573B2 JP2013508207A JP2013508207A JP5937573B2 JP 5937573 B2 JP5937573 B2 JP 5937573B2 JP 2013508207 A JP2013508207 A JP 2013508207A JP 2013508207 A JP2013508207 A JP 2013508207A JP 5937573 B2 JP5937573 B2 JP 5937573B2
- Authority
- JP
- Japan
- Prior art keywords
- methylcellulose
- individual
- gel
- stomach
- batch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title description 32
- 230000036186 satiety Effects 0.000 title description 22
- 235000019627 satiety Nutrition 0.000 title description 22
- 239000000203 mixture Substances 0.000 title description 10
- 230000001939 inductive effect Effects 0.000 title description 7
- 229920000609 methyl cellulose Polymers 0.000 claims description 74
- 239000001923 methylcellulose Substances 0.000 claims description 74
- 239000000499 gel Substances 0.000 claims description 71
- 210000002784 stomach Anatomy 0.000 claims description 37
- 239000007788 liquid Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 235000015872 dietary supplement Nutrition 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 8
- 230000036760 body temperature Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 25
- 239000000523 sample Substances 0.000 description 16
- 238000001879 gelation Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 229920002678 cellulose Polymers 0.000 description 11
- 239000001913 cellulose Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229920003086 cellulose ether Polymers 0.000 description 9
- 230000037406 food intake Effects 0.000 description 9
- 239000003518 caustics Substances 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000012022 methylating agents Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229920003091 Methocel™ Polymers 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000003736 gastrointestinal content Anatomy 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229920003108 Methocel™ A4M Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000019525 fullness Nutrition 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 230000037221 weight management Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008370 chocolate flavor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001595 flow curve Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021457 non-caloric beverage Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 235000019563 satiety test Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000001248 thermal gelation Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
栄養学的観点において、満腹は複雑な応答であり、十分に摂食したか否かの個体の感情的および物理的の両者の知覚の両者を含む。満腹は摂取の直後に続く食欲低下として、または次の食事での食物取込の低下として観測できる。本開示の目的で、「満腹」は個体によるカロリー取込の正味の低下を意味する。
一態様において、本発明は、個体によって摂食(ingest)された際に、個体の胃(Stomach)内でゲル塊(gel mass)を形成し、該ゲル塊がメチルセルロースから本質的になる、カロリー取込(intake)を低減するための薬剤または食品サプリメントを提供する。
セルロースは、1,4−結合で繋がった無水グルコース単位のポリマー骨格繰り返し構造を有する。各無水グルコース単位は、2,3および6位にヒドロキシル基を含有する。これらのヒドロキシルの置換はセルロース誘導体を形成する。例えば、苛性溶液、続いてメチル化剤でのセルロース繊維の処理は、1つ以上のメトキシ基で置換されたセルロースエーテルを与える。他のアルキルで更に置換されていない場合、このセルロース誘導体はメチルセルロースとして知られる。
以下の例は例示の目的のみであり、本発明の範囲の限定を意図しない。特記がない限り、全てのパーセントは質量基準である。
本発明に従って使用すべき例示の低温ゲル化メチルセルロースを、米国特許第6,235,893号に記載される方法に従って、得られる生成物が、ゲル塊の形成を約37℃未満(例えば多くの哺乳類,例えばマウス、ハムスターおよび人間のほぼ平熱)で開始するような条件で形成した。このメチルセルロースを以後バッチAという。
バッチAの溶液を、溶液を氷浴中で撹拌しなかったこと、および溶液を使用前に15分間撹拌しなかったことを除いて、実質的に例1で上記したように調製した。試料濃度0.70、0.90、1.10、1.30、1.50および1.70質量−体積%を調製した。各濃度の1.2mLの液体溶液(体重の約7.5mL/kg)を、試験前に16時間絶食(水は不断給餌)させたラットに3重強制飼養で与えた。45分後、ラットを犠牲にして解剖し、胃内容物を観察した。説明を表1に報告する。
バッチAの溶液を、溶液を氷浴中で撹拌しなかったことを除いて、実質的に例1で上記したように調製した。試料濃度0.70、0.90、1.10、1.30、1.50および1.70質量−体積%を調製した。
バッチAが、満腹について、従来のメチルセルロースと比べて統計的に有意な効果を有したか否かを評価するために、人間の臨床試験を依頼した。試験設計は、認定されたInstitutional Review Boardによってレビューされ、International Conference on Harmonization/Good Clinical Practice基準に基づいて実施された。
バッチA メチルセルロースについてのTgelは28℃である。
人間のボランティアの胃内のバッチAのゲル化および除去を示すために、磁気共鳴イメージング(MRI)を用いた臨床試験を行う。試験設計は、認定されたInstitutional Review Boardによってレビューされ、International Conference on Harmonization/Good Clinical Practice基準に基づいて実施される。
METHOCEL SGA16M メチルセルロースおよびMETHOCEL SGA7C メチルセルロースについてのTgelは各々38−44℃である。
バッチA メチルセルロースについてのTgelは28℃である。
以下もまた開示される。
[1] 個体に摂食された際に該個体の胃内でゲル塊を形成する、薬剤または食品サプリメントであって、該ゲル塊がメチルセルロースおよび水から本質的になる、薬剤または食品サプリメント。
[2] 該薬剤が、胃潰瘍、胃食道逆流症、または肥満を治療するのに有用である、上記[1]に記載の薬剤。
[3] 該薬剤または食品サプリメントが、減量補助剤として有用である、上記[1]に記載の薬剤または食品サプリメント。
[4] 該薬剤が、胃容積を少なくとも60分間、好ましくは少なくとも120分間、より好ましくは少なくとも180分間、およびより好ましくは少なくとも240分間満たすことを必要とする適応に有用である、上記[1]に記載の薬剤。
[5] 個体における満腹を誘導する方法であって、該個体に、該個体の胃内でゲル化するメチルセルロースを投与すること、を含む、方法。
[6] メチルセルロースが液体の形状で胃に入る、上記[5]に記載の方法。
[7] 該液体が少なくとも0.2質量%のメチルセルロースを含有する、上記[6]に記載の方法。
[8] 該個体が人間であり、該個体が、少なくとも3グラム超、好ましくは4グラム超のメチルセルロースを摂取する、上記[5]に記載の方法。
[9] 該個体が肥満体である、上記[8]に記載の方法。
[10] 該個体が肥満体でない、上記[8]に記載の方法。
[11] メチルセルロースが、胃に入った時点から少なくとも45分間でゲル化する、上記[5]または[6]に記載の方法。
[12] 個体における胃の空洞容積を可逆的に低減する方法であって、該個体に、該個体の胃内でゲル化するメチルセルロースを投与することを含む、方法。
[13] 該個体の胃のより少ない容積が食物に対して対応可能である、上記[12]に記載の方法。
[14] 該メチルセルロースが該個体の体温よりも低いゲル化点を有する、上記[13]に記載の方法。
[15] 個体におけるカロリー取込を低減する方法であって、
該個体に、該個体の胃内でゲル化するメチルセルロースを含む液体を投与することを含む、方法。
[16] 該個体の食事の少なくとも45分前にメチルセルロースを投与する、上記[15]に記載の方法。
[17] 該個体が人間であり、該個体が少なくとも6グラムのメチルセルロースを摂取する、上記[15]に記載の方法。
Claims (4)
- 個体に摂食された際に該個体の胃内でゲル塊を形成する、液体の薬剤または食品サプリメントであって、
該ゲル塊がメチルセルロースおよび水からなり、
該液体の薬剤または食品サプリメントが、1.5〜2.1質量%のメチルセルロースを含み、
該メチルセルロースが、無水グルコース単位あたりの平均メトキシル置換度1.47〜2.2および該個体の体温よりも低いゲル化点を有し、かつ、該液体の薬剤または食品サプリメントに対して、該液体の39.5℃および1時間での状態調整後のインビトロのゲル破砕力少なくとも1.5Nを与える、薬剤または食品サプリメント。 - メチルセルロースが、胃に入った時点から少なくとも45分間でゲル化する、請求項1に記載の薬剤または食品サプリメント。
- 該メチルセルロースが、該液体の薬剤または食品サプリメントに対してインビトロのゲル破砕力少なくとも4Nを与える、請求項1に記載の薬剤または食品サプリメント。
- 該メチルセルロースが、該液体の薬剤または食品サプリメントに対してインビトロのゲル破砕力少なくとも6Nを与える、請求項1に記載の薬剤または食品サプリメント。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32939610P | 2010-04-29 | 2010-04-29 | |
US61/329,396 | 2010-04-29 | ||
PCT/US2011/034129 WO2011139763A1 (en) | 2010-04-29 | 2011-04-27 | Methods and compositions for inducing satiety |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013525447A JP2013525447A (ja) | 2013-06-20 |
JP5937573B2 true JP5937573B2 (ja) | 2016-06-22 |
Family
ID=44281091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013508207A Expired - Fee Related JP5937573B2 (ja) | 2010-04-29 | 2011-04-27 | 満腹を誘導する方法および組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8623840B2 (ja) |
EP (1) | EP2563477A1 (ja) |
JP (1) | JP5937573B2 (ja) |
KR (1) | KR101827026B1 (ja) |
CN (1) | CN102905762B (ja) |
BR (1) | BR112012026848A2 (ja) |
MX (1) | MX338245B (ja) |
WO (1) | WO2011139763A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014CN02722A (ja) | 2011-10-19 | 2015-07-03 | Dow Global Technologies Llc | |
DK2768321T3 (da) | 2011-10-19 | 2020-08-31 | Dow Global Technologies Llc | Fremgangsmåder og sammensætninger til induktion af mæthed |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
CN105073869B (zh) * | 2013-04-12 | 2017-07-14 | 陶氏环球技术有限责任公司 | 用于制备甲基纤维素水溶液的方法 |
JP6408558B2 (ja) * | 2013-04-12 | 2018-10-17 | ダウ グローバル テクノロジーズ エルエルシー | 糖類及びメチルセルロースの水溶液を調製するための方法 |
WO2015009796A1 (en) * | 2013-07-17 | 2015-01-22 | Dow Global Technologies Llc | Composition for application to a mucosa comprising a methylcellulose |
KR20180015661A (ko) | 2015-06-05 | 2018-02-13 | 다우 글로벌 테크놀로지스 엘엘씨 | 셀룰로오스 에테르 분말 |
WO2016196152A1 (en) | 2015-06-05 | 2016-12-08 | Dow Global Technologies Llc | Cellulose ether powders |
US10188135B2 (en) * | 2015-11-04 | 2019-01-29 | Stokley-Van Camp, Inc. | Method for inducing satiety |
CN111279146B (zh) | 2017-06-04 | 2023-04-07 | 泰克年研究发展基金会公司 | 反向凝固组合物及其应用 |
WO2019022817A1 (en) | 2017-07-26 | 2019-01-31 | Dow Global Technologies Llc | PROCESS FOR PRODUCTION OF METHYLCELLULOSE-BASED HYDROGEL |
WO2019022821A1 (en) | 2017-07-26 | 2019-01-31 | Dow Global Technologies Llc | WATER-SOLUBLE POLYSACCHARIDES WITH ENHANCED SAPIDITY |
WO2019022822A1 (en) | 2017-07-26 | 2019-01-31 | Dow Global Technologies Llc | WATER-SOLUBLE POLYSACCHARIDES WITH IMPROVED PALABILITY |
WO2019108265A1 (en) | 2017-11-29 | 2019-06-06 | Dow Global Technologies Llc | Hydrogels based on methylcellulose |
JP7426316B2 (ja) | 2020-09-16 | 2024-02-01 | 日清食品ホールディングス株式会社 | メチルセルローススラリー及びその製造方法並びに該メチルセルローススラリーを含む肉様蛋白加工食品及びその製造方法 |
CN115429815B (zh) * | 2021-06-02 | 2023-12-22 | 广州帝奇医药技术有限公司 | 一种长效饱腹组合物、制备方法及用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB745926A (en) | 1952-11-20 | 1956-03-07 | Merck & Co Inc | Improvements in or relating to wafers and the like bakery products |
US4042719A (en) * | 1972-02-25 | 1977-08-16 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt | Compositions of low calory content |
JPH0649768B2 (ja) * | 1985-06-06 | 1994-06-29 | 信越化学工業株式会社 | 水性ゲルの製造方法 |
JPH04164025A (ja) * | 1990-10-25 | 1992-06-09 | Shin Etsu Chem Co Ltd | 徐放性錠剤の製造方法 |
SE9003713L (sv) * | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | Gelbildande flytande dietfiberkomposition |
US6235893B1 (en) | 1999-04-01 | 2001-05-22 | The Dow Chemical Company | Process for making cellulose ether having enhanced gel strength |
WO2000059947A1 (en) * | 1999-04-01 | 2000-10-12 | The Dow Chemical Company | Enhanced gel strength methylcellulose |
DE10160409A1 (de) * | 2001-12-10 | 2003-06-18 | Guenther Beisel | Verwendung von ionischen und nichtionischen Celluloseethern zur Herstellung eines gelartigen Mittels zur Verhinderung der Resorption von Fetten aus dem Magen-Darm-Trakt |
US6989166B2 (en) | 2001-12-20 | 2006-01-24 | N.V. Nutricia | Soft drink replacer |
RU2196604C1 (ru) | 2001-12-21 | 2003-01-20 | Северин Евгений Сергеевич | Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе |
RU2354145C2 (ru) | 2003-09-03 | 2009-05-10 | Юнилевер Н.В. | Пищевые композиции, усиливающие чувство сытости |
WO2005020719A1 (en) * | 2003-09-03 | 2005-03-10 | Unilever N.V. | Satiety enhancing food compositions |
WO2007039294A2 (en) | 2005-10-05 | 2007-04-12 | Fmc Biopolymer As | Gelling compositions and methods |
-
2011
- 2011-04-27 EP EP11717907A patent/EP2563477A1/en not_active Withdrawn
- 2011-04-27 MX MX2012012616A patent/MX338245B/es active IP Right Grant
- 2011-04-27 WO PCT/US2011/034129 patent/WO2011139763A1/en active Application Filing
- 2011-04-27 US US13/095,414 patent/US8623840B2/en not_active Expired - Fee Related
- 2011-04-27 BR BR112012026848A patent/BR112012026848A2/pt not_active Application Discontinuation
- 2011-04-27 JP JP2013508207A patent/JP5937573B2/ja not_active Expired - Fee Related
- 2011-04-27 KR KR1020127031142A patent/KR101827026B1/ko active IP Right Grant
- 2011-04-27 CN CN201180021397.7A patent/CN102905762B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8623840B2 (en) | 2014-01-07 |
KR101827026B1 (ko) | 2018-02-07 |
WO2011139763A1 (en) | 2011-11-10 |
KR20130062286A (ko) | 2013-06-12 |
US20110269711A1 (en) | 2011-11-03 |
BR112012026848A2 (pt) | 2017-10-17 |
JP2013525447A (ja) | 2013-06-20 |
CN102905762B (zh) | 2017-02-15 |
EP2563477A1 (en) | 2013-03-06 |
MX338245B (es) | 2016-04-08 |
CN102905762A (zh) | 2013-01-30 |
MX2012012616A (es) | 2012-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5937573B2 (ja) | 満腹を誘導する方法および組成物 | |
JP6934849B2 (ja) | 体重管理用および血糖管理用の方法および組成物 | |
JP6073342B2 (ja) | 満腹を誘導する方法および組成物 | |
JP6208671B2 (ja) | 満腹を誘導する方法および組成物 | |
CN114403403A (zh) | 一种具有减脂减重功效的果冻及其制备方法 | |
JPWO2008053984A1 (ja) | アロエおよび寒天を含有した健康食品 | |
US20220117281A1 (en) | Satiety inducing food products and preparation thereof | |
US20190298757A1 (en) | Edible semi-solid composition for use in patients undergoing endoscopy including colonoscopy | |
US20070134383A1 (en) | Z-Trim combined directly with erythritol | |
Anderson et al. | Adden et a].(45) Date of Patent: Jan. 7, 2014 | |
Ho | Development of beverage model to test appetite control food ingredients: a thesis presented in partial fulfilment of the requirements for the degree of Master of Technology in Food Technology at Massey University, Palmerston North, New Zealand | |
WILLIAMS | Nourishment in Acute Disease | |
JP2011026217A (ja) | 月経痛緩和剤 | |
KR20140112711A (ko) | 방광과체질인에 대한 혈당강하용 커피 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160412 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160512 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5937573 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |